Next-generation sequencing market projected to hit $57.54 billion by 2033

By AI, Created 12:18 PM UTC, May 18, 2026, /AGP/ – A new Coherent Market Insights report estimates the next-generation sequencing market will grow from $21.76 billion in 2026 to $57.54 billion by 2033. The study breaks down key segments, regions and competitive players as demand rises across diagnostics, drug discovery and personalized medicine.

Why it matters: - The next-generation sequencing market is projected to more than double by 2033, signaling continued demand for genomic tools in research and clinical use. - The forecast points to growing commercial opportunities in diagnostics, drug discovery and personalized medicine. - The report is aimed at companies, investors and industry participants that need market sizing, segment data and competitive benchmarking.

What happened: - Coherent Market Insights published a forecast report on the next-generation sequencing market covering 2026 to 2033. - The report estimates the market at $21.76 billion in 2026 and $57.54 billion by 2033. - The study was released from Burlingame, California, on May 18, 2026. - A sample copy is available here.

The details: - The report analyzes the market by product type, sequencing type, application and end user. - Product types include instruments and reagents and consumables. - Sequencing categories include whole genome sequencing, whole exome sequencing, RNA sequencing, targeted re-sequencing and other methods. - Applications covered include drug discovery, personalized medicine, genetic screening, diagnostics and others. - End users include hospitals and clinics, academic and research institutes, biopharmaceutical companies, clinical laboratories and others. - The report includes global and country-level forecasts, competitive landscape analysis, supply chain evaluation and SWOT analysis. - The study also examines market drivers, restraints, trends, opportunities and challenges. - Regional coverage spans North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. - Companies named in the report include Thermo Fisher Scientific, Agilent Technologies, bioMérieux, F. Hoffmann-La Roche, QIAGEN, Illumina, Oxford Nanopore Technologies, BGI, PerkinElmer Genomics, Bio-Rad Laboratories, Pacific Biosciences, 10x Genomics, Promega, Macrogen, Eurofins Scientific, DNASTAR and CD Genomics.

Between the lines: - The report’s emphasis on revenue share, segment profitability and regional consumption suggests the market is becoming more competitive and more segmented. - Inclusion of both established sequencing leaders and newer players points to a market where technology, scale and product mix all matter. - The focus on expansions, launches, acquisitions and collaborations signals that growth may come as much from strategic dealmaking as from organic demand.

What’s next: - Coherent Market Insights says the updated report and online dashboard are designed to help buyers track historical data, future forecasts and industry shifts. - The report says it can support strategic planning, investment decisions and competitive positioning. - The company also offers purchase and sample-request options through its website, including a discounted premium report offer.

The bottom line: - The next-generation sequencing market is set for strong expansion through 2033, with the biggest upside centered on clinical adoption, research demand and platform competition.